GlassScriptPhysician profile
Kristina E Harp
NPI 1730296948
$774.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $200.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $79.59 | 2019 | |
| Pfizer INC. | $72.28 | 2019 | |
| Amgen INC. | $71.18 | 2019 | |
| Abbvie INC. | $54.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.18 | 2019 | |
| Amneal Pharmaceuticals LLC | $36.15 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $29.60 | 2019 | |
| Allergan, INC. | $29.05 | 2019 | |
| Merck Sharp & Dohme LLC | $27.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.50 | 2019 | |
| Shire North American Group INC | $22.11 | 2019 | |
| Astellas Pharma US INC | $19.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.07 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $12.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.